Selective optimization of side activities: the SOSA approach (Q34565597)

3 August 2017

1 reference

title

Selective optimization of side activities: the SOSA approach (English)

1 reference

3 August 2017

Camille G Wermuth

1

1 reference

3 August 2017

1 February 2006

1 reference

3 August 2017

1 reference

3 August 2017

11

1 reference

3 August 2017

3-4

1 reference

3 August 2017

160-164

1 reference

The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98).

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

The benzodiazepine story

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Selective optimization of side activities: another way for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Dopamine-like activities of an aminopyridazine derivative, CM 30366: a behavioural study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

The biotransformation of [14C]minaprine in man and five animals species

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Neurochemical effects of minaprine, a novel psychotropic drug, on the central cholinergic system of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Aminopyridazines as acetylcholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) sele

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Discovering transthyretin amyloid fibril inhibitors by limited screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Molecular properties that influence the oral bioavailability of drug candidates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Absorption classification of oral drugs based on molecular surface properties

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

A comparison of physiochemical property profiles of development and marketed oral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A: design, synthesis, and biological activity of cladinose replacement analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Drugs, leads, and drug-likeness: an analysis of some recently launched drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Is there a difference between leads and drugs? A historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

BMS-192548, a tetracyclic binding inhibitor of neuropeptide Y receptors, from Aspergillus niger WB2346. II. Physico-chemical properties and structural characterization.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

Imidazole analogues of fluoxetine, a novel class of anti-Candida agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903686-X

7 January 2021

10.1016/S1359-6446(05)03686-X

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

16533714